It is well-known that patients may respond in a variable and sometimes unpredictable manner to surgery, anesthetic agents, and other interventions. All these factors induce changes in cardiac output, which is the main determinant of oxygen delivery to the tissues. Up to now, routine monitoring during most procedures in the Operating Room only includes basic vital signs. This is, however, not enough to identify a decrease in cardiac output occurring during hemodynamic deterioration.
Additionally, there is extensive evidence that Goal-Directed Therapies (GDT) for patient optimization improve outcome and reduce Length of Stay in the hospital. However, such therapies are limited to the use of invasive intra-arterial lines or other invasive methods. In the US, only 16% of the surgical patients get an intra-arterial line. This leaves a great number of patients, many of whom are at risk for decreased cardiac output, without the option to benefit from hemodynamic optimization.
BMEYE's non-invasive technology available in ccNexfin, makes advanced hemodynamic monitoring available to far more patients, preventing unnecessary complications that affect quality of care, while at the same time reducing healthcare costs. This is a giant step forward for medicine.